Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1

BACKGROUND: Anti-programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) monoclonal antibodies (mAbs) show remarkable clinical anti-tumour efficacy. However, rational combinations are needed to extend the clinical benefit to primary resistant tumours. The design of such combinations require...

Descripción completa

Detalles Bibliográficos
Autores principales: Zalba, Sara, Belsúe, Virginia, Topp, Brian, de Alwis, Dinesh, Alvarez, Maite, Trocóniz, Iñaki F., Berraondo, Pedro, Garrido, María J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007692/
https://www.ncbi.nlm.nih.gov/pubmed/33531689
http://dx.doi.org/10.1038/s41416-020-01239-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007692/
https://www.ncbi.nlm.nih.gov/pubmed/33531689
http://dx.doi.org/10.1038/s41416-020-01239-z

Ejemplares similares